Trial
NCT06035744
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Cullinan Therapeutics Inc.
Collaborators
—
Condition
Advanced Solid Tumor
Intervention
CLN-617
Why stopped
Company decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-18